Komunikaty PR

Global Scientific Instruments Market Outlook 2025-2034: Growth Drivers, Share, And Trends

2025-05-23  |  14:55:06
The Business Research Company

The Business Research Company

The Business Research Company’s Scientific Instruments Global Market Report 2025 – Market Size, Trends, And Forecast 2025-2034

The Business Research Company’s Latest Report Explores Market Driver, Trends, Regional Insights - Market Sizing & Forecasts Through 2034”
— The Business Research Company

LONDON, GREATER LONDON, UNITED KINGDOM, May 23, 2025 /EINPresswire.com/ -- The scientific instruments market size has grown decidedly in recent years, projecting a growth from $42.95 billion in 2024 to $45.24 billion in 2025. This significant leap represents a compound annual growth rate CAGR of 5.3%. In the historical perspective, this growth can be attributed to an increased focus on life sciences, substantial government funding for scientific research, stringent environmental monitoring, the increasing complexity of scientific inquiries, and the broader spectrum of research globalization.

Are there projections for further growth in the scientific instruments market?
The momentum doesn't stop here as the scientific instruments market size is set to see dynamic growth in the near future. Forecasts peg the market to swell to $59.77 billion in 2029, reflecting a compound annual growth rate CAGR of 7.2%. The surge in the forecast period is attributable to the implementation of precision medicine and personalized healthcare, the rise of point-of-care testing, the emergence of regenerative medicine, custom-made and modular instrument design, regulatory compliance, and quality assurance.

Get Your Free Sample Market Report:
https://www.thebusinessresearchcompany.com/sample_request?id=8125&type=smp

What's driving this growth in the scientific instruments market?
The rapid increase in testing and research facilities due to the spreading virus and intensifying efforts to combat its aftereffects. These facilities necessitate scientific instruments for effective testing and the development of suitable solutions. During the forecast period, major market trends encompass increased demand for biotechnology, the rise of sustainable and green technologies, expanded application of multi-modal imaging systems, applications in material science, enhanced connectivity and data sharing and an overall expansion of research and development R&D activities.

What companies are spearheading the development of the scientific instruments market?
The major shareholders in the scientific instruments market include Thermo Fisher Scientific Inc., Agilent Technologies Inc., Bruker Corporation, Danaher Corporation, Waters Corporation, The Merck Group, Horiba Limited, PerkinElmer Inc., F. Hoffmann-La Roche AG, Carl Zeiss AG, Shimadzu Corporation, Mettler-Toledo International Inc., Oxford Instruments PLC, EppendoRF AG, JEOL Ltd., Hitachi High-Technologies Corporation, Malvern Panalytical GmbH, Bio-Rad Laboratories Inc., Becton Dickinson and Company, Illumina Inc., Bio-Techne Corporation, Sartorius AG, Hamilton Company, Siemens Healthineers AG, Koninklijke Philips N.V. Healthcare.

Order Your Report Now For A Swift Delivery:
https://www.thebusinessresearchcompany.com/report/scientific-instruments-global-market-report

What are the emerging trends in the scientific instruments market?
These companies are taking advantage of an emerging trend in the scientific instruments market – the rise of artificial intelligence. Artificial intelligence in research is presumed to significantly alter current practices and offers key players a competitive advantage in the marketplace.

How is the scientific instruments market segmented?
When looking at market segmentation, the scientific instruments market report covers: by type – Clinical Analyzers, Analytical Instruments, Other Types; by application – Research, Clinical And Diagnostics, Other Applications; by the end-user – Hospitals And Diagnostic Laboratories, Pharmaceutical And Biotechnology Companies, Other End-Users. Subsegments include clinical analyzers types like Hematology Analyzers, Biochemistry Analyzers, Immunoassay Analyzers, and other types such as Microscopes, Laboratory Balances, Environmental Testing Instruments.

What are the regional insights into the scientific instruments market?
On the regional front, North America led the scientific instruments market in 2024, but the crown for the fastest-growing region during the forecast period goes to Asia-Pacific. Other regions covered in the market report include Western Europe, Eastern Europe, South America, Middle East, and Africa.

Browse Through More Similar Reports By The Business Research Company:
Pharmaceutical API Manufacturing Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/pharmaceutical-api-manufacturing-global-market-report

Laboratory Accessories Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/laboratory-accessories-global-market-report

Medical Equipment Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/medical-equipment-global-market-report

About The Business Research Company
Learn More About The Business Research Company. With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info

Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Oliver Guirdham
The Business Research Company
+44 20 7193 0708
info|tbrc.info| |info|tbrc.info
Visit us on social media:
LinkedIn
Facebook
X

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Newseria nie ponosi odpowiedzialności za treści oraz inne materiały (np. infografiki, zdjęcia) przekazywane w „Biurze Prasowym”, których autorami są zarejestrowani użytkownicy tacy jak agencje PR, firmy czy instytucje państwowe.
Ostatnio dodane
komunikaty PR z wybranej przez Ciebie kategorii
EIN Newswire BRAK ZDJĘCIA
2025-06-17 | 03:55:06

NEXCOM EBC 370 Powers Autonomous Robotics for Industrial Applications

Highly Efficient, Edge AI Computing Delivered in a Compact New CPUThe EBC 370/EBC 370X is an AI-powered, PC-based controller designed to adapt to the most demanding conditions. Research labs use it as the main control unit for advanced robotics
EIN Newswire BRAK ZDJĘCIA
2025-06-17 | 03:55:06

The End Brain Cancer Initiative Partners with Curis to Pre-qualify for PCNSL TakeAim Lymphoma Clinical Trial

The End Brain Cancer Initiative Partners with Curis to Promote Awareness and Pre-qualify for PCNSL TakeAim Lymphoma Clinical Trial REDMOND, WA, UNITED STATES, June 16, 2025 /EINPresswire.com/ -- FOR IMMEDIATE RELEASE Contact: Dellann Elliott Mydland, 425-785-8489, Dellann@EndBrainCancer.org The End Brain Cancer Initiative Partners with Curis to Promote Awareness and Pre-qualify for PCNSL TakeAim Lymphoma Clinical Trial The End Brain Cancer Initiative (EBCI) has partnered with Curis to promote awareness and pre-qualify patients for the company’s TakeAim Lymphoma Clinical Trial (CA-4948-101) clinical trial, an open-label, dose escalation and expansion trial of Emavusertib in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/​R PCNSL) (NCT03328078). “We are proud to partner with the End Brain Cancer Initiative to help raise awareness for primary CNS lymphoma (PCNSL), a rare and challenging form of cancer non-Hodgkin lymphoma. Together, we aim to highlight the unmet medical needs of this patient community, provide relevant resources to patients and their care providers, along with increasing awareness of clinical trials,” shared the Chief Medical Officer of Curis Inc, Ahmed Hamdy, MD. “Curis is committed to developing emavusertib for the treatment of PCNSL and broader non-Hodgkin lymphoma indications.” Patients who would like to learn more about this clinical trial and see if they qualify can visit https://endbraincancer.org/curis-therapeutics/ or contact the End Brain Cancer Initiative’s Clinical Research Coordinator and Patient Navigator, Shreya Prakash, at Shreya@EndBrainCancer.org or 425-436-8688. About Curis Curis, located in Lexington, Massachusetts, is a biotechnology company focused on the development of Emavusertib, an orally available, small molecule IRAK4 inhibitor. Emavusertib is currently being evaluated in the TakeAim Lymphoma Phase 1/2 study (CA-4948-101) in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) in combination with the BTK inhibitor ibrutinib, as a monotherapy in the TakeAim Leukemia Phase 1/2 study (CA-4948-102) in patients with relapsed/refractory acute myeloid leukemia (AML) and relapsed/refractory high risk myelodysplastic syndrome (hrMDS), and as a frontline combination therapy with venetoclax and azacitidine in patents with AML (CA-4948-104). Emavusertib has received Orphan Drug Designation from the U.S. Food and Drug Administration for the treatment of PCNSL, AML and MDS and from the European Commission for the treatment of PCNSL. Curis, through its 2015 collaboration with Aurigene, has the exclusive license to Emavusertib (CA-4948). Curis licensed its rights to Erivedge® to Genentech, a member of the Roche Group, under which they are commercializing Erivedge® for the treatment of advanced basal cell carcinoma. For more information, visit Curis's website at https://www.curis.com/. About the End Brain Cancer Initiative To support/donate to the End Brain Cancer Initiative’s increased access and health delivery for patients, mission, services and programs, please visit EndBrainCancer.org The End Brain Cancer Initiative (EBCI) is a 501(c)3 non-profit patient advocacy organization focused on disease education, awareness, outreach, increasing patient access and improving Standard of Care. The End Brain Cancer Initiative, formerly known as the Chris Elliott Fund (CEF), is dedicated to ensuring that all patients diagnosed with brain cancer, a brain tumor, or metastatic disease to the brain have equal access to advanced diagnostics, treatments, specialists, and clinical trial participation. We believe that IMMEDIATE ACCESS to these options provides this patient community with the best HOPE for survival and sustained quality of life. We partner with industry, patients, researchers, advocacy groups, medical teams, hospital networks and others to educate patients and their caregivers so they can have empowered conversations with their medical teams. Learn more about the End Brain Cancer Initiative or how to sponsor this annual campaign at EndBrainCancer.org. Dellann Elliott Mydland, End Brain Cancer Initiative, 425-785-8489, Dellann@EndBrainCancer.org
EIN Newswire BRAK ZDJĘCIA
2025-06-17 | 02:55:04

Uncle Sharkii Poke Bar Franchisees Honored with Multi-Unit Mastery Award

Uncle Sharkii franchisees Bruno and Jessica Picelli with the 2024 Multi-Unit Mastery Award.The award recognizes the longtime franchisees’ successful leadership and operational excellence across five Uncle Sharkii Poke Bar locations.From day

Kalendarium

Więcej ważnych informacji

Jedynka Newserii

Jedynka Newserii

Kongres Profesjonalistów Public Relations

Ochrona środowiska

Z powodu braku przejrzystego prawa branża recyklingu odkłada inwestycje. Firmy apelują o szybkie wdrożenie przepisów

Branża recyklingu stoi przed wyzwaniami związanymi z wdrożeniem systemu kaucyjnego, systemu rozszerzonej odpowiedzialności producenta i rozporządzenia PPWR. Brakuje jednak odpowiednich przepisów dostosowujących polskie prawo i realia do unijnych regulacji. W efekcie utrzymującej się niepewności prawnej między 2018 a 2023 rokiem co trzeci zakład recyklingu zamknął działalność. Wiele firm odkłada inwestycje, czekając na uregulowanie rynku. Podobna niepewność dotyczy też producentów opakowań. 

Transport

Testowanie pojazdów zautomatyzowanych wkrótce będzie możliwe. To odpowiedź na postulaty przedsiębiorców

Kończą się prace nad przepisami, które mają usprawnić prace badawcze nad pojazdami zautomatyzowanymi. Ma to być odpowiedź na postulaty przedsiębiorców, którzy wskazywali na potrzebę pilnej zmiany przepisów w zakresie testowania pojazdów autonomicznych. Obecne regulacje nie sprzyjają postępowi technologicznemu i rozwoju autonomiczności pojazdów, o czym świadczy bardzo niewielka liczba wydanych uprawnień do ich prowadzenia.

Firma

Przedsiębiorcom coraz bardziej doskwiera niestabilność i skomplikowanie przepisów podatkowych. Problemem są też niejasne ich interpretacje

Polscy przedsiębiorcy często negatywnie oceniają jakość przepisów podatkowych – wynika z raportu „Przedsiębiorcy pod lupą fiskusa 2025” przygotowanego przez firmę doradztwa podatkowego MDDP we współpracy z Konfederacją Lewiatan. Ich niepokój budzą niejednolite interpretacje przepisów i niepewność prawa podatkowego, które cały czas jest modyfikowane. Wśród kluczowych zmian w obszarze podatków, które będą dotyczyć praktycznie wszystkich przedsiębiorców, są m.in. wprowadzenie Krajowego Systemu e-Faktur czy zmiany w podatku od nieruchomości.

Partner serwisu

Instytut Monitorowania Mediów

Szkolenia

Akademia Newserii

Akademia Newserii to projekt, w ramach którego najlepsi polscy dziennikarze biznesowi, giełdowi oraz lifestylowi, a  także szkoleniowcy z wieloletnim doświadczeniem dzielą się swoją wiedzą nt. pracy z mediami.